News Sobi starts rolling FDA filing for chronic gout drug Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu
News Sobi plans filings for gout drug after phase 3 readout SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.
News AZ considers options as US gout drug deal backfires Ironwood tears up licensing agreement after sales disappoint
News FDA approves Ironwood's gout combination drug Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
News AZ sells US, EU and Latin America rights to gout drug AZ focused on sales target set by CEO Pascal Soriot.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.